Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. - Wikidata - wikimedia - TriplyDB

Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.

Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.

http://www.wikidata.org/entity/Q37412327

about

Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Regulatory T cell: a protection for tumour cells Targeting the innate immune system as immunotherapy for acute myeloid leukemia Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia.Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.Allogeneic natural killer cells for refractory lymphoma Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.Tumor-secreted miR-214 induces regulatory T cells: a major link between immune evasion and tumor growth Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes Minimal residual disease following allogeneic hematopoietic stem cell transplantation.New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?Scaffold protein Disc large homolog 1 is required for T-cell receptor-induced activation of regulatory T-cell function.Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells.Elevated lymphocyte count at time of acute myeloid leukemia diagnosis is associated with shorter remission.Programmed death-1 checkpoint blockade in acute myeloid leukemia.A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.How to detour Treg cells in T cell-based antitumor immune therapy.The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT).Enhancing adoptive immunotherapy of cancer.Immunotherapy prospects for acute myeloid leukaemia.T regulatory cells in cancer: recent advances and therapeutic potential.Use of allogeneic NK cells for cancer immunotherapy.Immune evasion in acute myeloid leukemia: current concepts and future directions.The targeting of immunosuppressive mechanisms in hematological malignancies.Umbilical cord blood graft engineering: challenges and opportunities.Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression.Increased regulatory T cells in acute lymphoblastic leukemia patients.Mechanisms of Immune Tolerance in Leukemia and Lymphoma.Increased regulatory T cells in acute lymphoblastic leukaemia patients.Extracts of Devil's club (Oplopanax horridus) exert therapeutic efficacy in experimental models of acute myeloid leukemia.Cancer-derived exosomic microRNAs shape the immune system within the tumor microenvironment: State of the art.Monocyte chemoattractant protein 1 (MCP-1/CCL2) contributes to thymus atrophy in acute myeloid leukemia.A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines.Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells.

P2860

Q26770391-9CFBCBD9-99C7-4FEF-9E9C-62137FECC15E Q26991447-3B58130C-5FD2-4BAD-B19F-BD31C24EAED9 Q27015876-C8D4D8C7-D194-4591-8072-CA90CDEDF503 Q33734571-56E95B11-0F7F-4502-92DA-0628E64AC76D Q33781150-28EFF971-B510-4CEA-9BBA-D6D515DF1979 Q33850138-6A7F58A3-85FF-4BC5-AAD3-8EC20BE969B4 Q34193534-9D663DEB-771C-4159-9D6B-A4CF9B2231A9 Q34289902-90045B9D-3340-42B4-86D6-41B207CD7490 Q34473451-0911DD62-2045-44DB-BA4D-A01C4CCCEFA2 Q34557896-C8068CFB-F6FF-4EC4-8234-F11F72FE20D2 Q34664957-65905FCC-CE64-4D95-9FA7-1BF78F7AB256 Q34667390-AF928507-CCF0-4FB3-B118-0EE9B8F7BF4C Q34715598-C1DC7A9C-6C93-481C-9BB4-E69AFAB63ECD Q34997704-D70FE6B5-63E3-471E-8994-E0852143B9D0 Q35553553-CD4297D5-30C2-4C35-B97C-C1AE121495BD Q35749767-05343B23-C312-4F3C-AC35-80D5288C9255 Q36057599-8D1109DE-D107-491B-BC67-83AEF27D19A5 Q36467544-5CFEBD31-0137-442A-8A00-B31B659DCB7D Q36652124-18F819D8-FEA5-4CC5-98A5-62F8FE18BEA5 Q37141237-CF586180-626B-416E-A541-C0538E924B2F Q37169964-698FCA2D-10C2-4B1A-AE28-1D40914F9E4B Q37589671-F890D99B-3605-4E5E-B573-976E674E2DA3 Q37687429-CCF7269C-9177-4BDE-AC35-8DE5A240B4E4 Q37763280-25813121-8B75-4AB5-9E7E-B83619748E0F Q37800935-DF756D5A-5218-4D5D-8032-CA27BB692995 Q37957140-04C93FDF-5B1B-4AE1-9904-0086E3A5D906 Q38172521-A7921605-1175-4AAE-A3D6-9CBB6905FF10 Q38201231-7E44B875-65DD-47FB-8BED-84C0C5240C83 Q38514503-4CD935A0-F8F6-4C59-8EDC-63167FE5C747 Q38525024-3A05B485-FDBC-407B-9E0B-CE913E3D2083 Q38539663-01CD718F-FB5B-4B57-AD21-E3EB287144E2 Q38683034-B1467EC2-70B0-4C3B-BB89-278C139C7A73 Q38747439-A112D105-8CE0-4A42-ACEA-24735BC5C63F Q38945605-AFC3E655-EB8D-40FB-8754-B9BD8E8CD007 Q39036722-33F121E9-F490-415E-A2CD-284BDCD107F3 Q39100783-C4ABE96E-29E4-41A5-B8D3-31E4F677187D Q41273685-C7E4C3BE-DE0E-4F90-87F2-416CFACBE5F9 Q41573313-D7CD6810-8D94-4691-9273-565024E09638 Q42186082-ECA6BA68-F1EF-4D3C-BE7A-D760D6F8E30D Q42572959-3D7F0358-075C-4F7A-B6DB-15E1047C10F7

P2860

Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.

http://www.wikidata.org/entity/Q37412327

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Depletion of endogenous tumor- ...... murine acute myeloid leukemia.

@en

Depletion of endogenous tumor- ...... murine acute myeloid leukemia.

@nl

type

label

Depletion of endogenous tumor- ...... murine acute myeloid leukemia.

@en

Depletion of endogenous tumor- ...... murine acute myeloid leukemia.

@nl

prefLabel

Depletion of endogenous tumor- ...... murine acute myeloid leukemia.

@en

Depletion of endogenous tumor- ...... murine acute myeloid leukemia.

@nl

P1433

Q37412327-F94B76B5-7552-4BC2-AA95-659313F5988E

P1476

Q37412327-3C741A7D-464B-468A-9147-8EF5C90E244E

P2093

Q37412327-018A786B-B694-4C35-8AE5-C7A7657C52BF

Q37412327-1869840F-9F6D-41A3-B8D0-701E675367DC

Q37412327-38630B74-BBBA-4A0F-9486-1C5D87251E11

Q37412327-3CEC255D-0586-4A2E-8F65-FD76C66366E4

Q37412327-3EACA173-A65E-4EDE-8963-09AA35F0A029

Q37412327-6B6216F7-935E-402D-81E0-A3F278C6D815

Q37412327-883262DF-6408-4CAE-9CDB-B4EA18A1BA96

Q37412327-9AAF73F4-6FD6-457C-90A8-8D307C4FA7DF

Q37412327-CC67AE9C-58C9-4E8B-A268-BF13F99EDA0C

Q37412327-E2F542F9-0CB7-4F01-9224-462F17E8098C

P2860

Q37412327-047C8BEA-F25F-49EF-8446-ED05E83534C1

Q37412327-054E420C-D098-425D-9CAD-334B89DF7C9F

Q37412327-089E7220-251B-4817-B1B1-0511AA6B786A

Q37412327-135CE2A9-6C45-4BFC-AE0B-F52285AD16B2

Q37412327-1605DEAD-3A5B-4773-A92D-1952F6D695F3

Q37412327-16C69A76-1964-4B14-86DB-C6AFA78A4C8F

Q37412327-1B192899-5A99-482C-A19C-049D2FBAE277

Q37412327-1D91B9C6-ACEF-4EA2-8537-7282E6ADB8AB

Q37412327-21C81AE2-DE86-416A-9DF0-660D12190B77

Q37412327-2BBDC7A7-6EE5-4C0D-977B-21C9769661EE

P304

Q37412327-BAE78B8F-2ADD-45DA-9C39-0DF61CAC358F

P31

Q37412327-A17A6DE3-FCAF-4990-AB23-B6E12BC08636

P356

Q37412327-B418BC89-D31E-4253-AC8B-EC29E50ACEB1

P407

Q37412327-5E0E8CE2-8185-4CAF-84F4-66B9EC5C5039

P433

Q37412327-8B27F492-A2C3-4BEF-AF89-C643A2F4D959

P478

Q37412327-1D3DB09A-6B26-4F7F-B499-93350D765058

P50

Q37412327-4BC822F8-8377-4866-871B-97221027FD4A

Q37412327-C3591460-E144-400B-95A3-73A1008042ED

P577

Q37412327-CE412D78-1186-452C-B36C-48899BE8D2F4

P698

Q37412327-37E08781-944E-40CB-AB14-2DC2248C4C34

P921

Q37412327-5E6F8AC8-B6B8-4852-AF43-840D0CDECFA8

Q37412327-968D01C7-DC6F-40D6-87AC-405906904529

Q37412327-9CD4CB81-ED0E-4793-8FCE-EC61CD1A678A

P932

Q37412327-2E4D7BCF-E332-4A57-AB2C-92C59D10B22E

P356

BLOOD-2009-03-208181

P1433

P1476

Depletion of endogenous tumor- ...... murine acute myeloid leukemia.

@en

P2093

Brenda J Weigel

http://www.w3.org/2001/XMLSchema#string

Bruce L Levine

http://www.w3.org/2001/XMLSchema#string

Carl H June

http://www.w3.org/2001/XMLSchema#string

Christoph Bucher

http://www.w3.org/2001/XMLSchema#string

Daniel A Vallera

http://www.w3.org/2001/XMLSchema#string

David H Munn

http://www.w3.org/2001/XMLSchema#string

Megan Riddle

http://www.w3.org/2001/XMLSchema#string

Meghan E Munger

http://www.w3.org/2001/XMLSchema#string

Qing Zhou

http://www.w3.org/2001/XMLSchema#string

Steven L Highfill

http://www.w3.org/2001/XMLSchema#string

P2860

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.

Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.

Strategies to overcome obstacles to successful immunotherapy of melanoma

Fluticasone propionate increases CD4CD25 T regulatory cell suppression of allergen-stimulated CD4CD25 T cells by an IL-10-dependent mechanism.

Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation.

Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy

Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission.

P304

3793-3802

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-03-208181

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19724059

http://www.w3.org/2001/XMLSchema#string

P921

P932

2773484

http://www.w3.org/2001/XMLSchema#string